

CBLB Knockout cell line (A549)

Catalog Number: KO38669

| Product Information | |
|----------------------------|--|
| Product Name | CBLB Knockout cell line (A549) |
| specification | 1*10^6 |
| Storage and transportation | Dry ice preservation/T25 live cell transportation. |
| Cell morphology | Epithelioid, adherent cell |
| Passage ratio | 1:3~1:4 |
| species | Human |
| Gene | CBLB |
| Gene ID | 868 |
| Build method | Electric rotation method / virus method |
| Mycoplasma testing | Negative |
| Cultivation system | 90% F12K+10% FBS |
| Parental Cell Line | A549 |
| Quality Control | Genotype: CBLB Knockout cell line (A549) >95% viability before freezing. All cells were tested and found to be free of bacterial, viruses,mycoplasma and other toxins. |

| Gene Information | |
|-------------------------|--|
| Gene Official Full Name | Cbl proto-oncogene Bprovided by HGNC |
| Also known as | Cbl-b; RNF56; ADMIO3; Nbla00127 |
| Gene Description | This gene encodes an E3 ubiquitin-protein ligase which promotes proteosome-mediated protein degradation by transferring ubiquitin from an E2 ubiquitin-conjugating enzyme to a substrate. The encoded protein is involved in the regulation of immune response by limiting T-cell receptor, B-cell receptor, and high affinity immunoglobulin epsilon receptor activation. Studies in mouse suggest that this gene is involved in antifungal host defense and that its inhibition leads to increased fungal killing. Manipulation of this gene may be beneficial in implementing immunotherapies for a variety of conditions, including cancer, autoimmune diseases, allergies, and infections. [provided by RefSeq, Sep 2017] |
| Expression | Ubiquitous expression in lymph node (RPKM 6.7), gall bladder (RPKM 4.7) and 25 other tissues See more |

